BARDA boosts the fight against antibiotic-resistant infections with $144M awards
In a first, BARDA has offered a $76.9 million award to fund a microbiome-based therapy’s last dash toward the FDA while promising $77 million for a late-stage program combining CRISPR tech and bacteriophages.
Both drugs are designed to address antibiotic-resistant infections, with Vedanta’s VE303 aimed at C. difficile infections and Locus Biosciences’ LBP-EC01 intended to treat recurrent UTIs caused by E. coli.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.